Will argenx SE (ARGX) Deliver Solid Performance in Near-Term?

Baron Funds, an investment management company, released its “Baron Opportunity Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 2.38% (Institutional Shares) compared to a 3.37% decline for the Russell 3000 Growth Index and a 4.88% decline for the S&P 500 Index.  The fund fell sharply for the year-to-date and trailing 12-month periods; however, the philosophy of the fund is to achieve strong long-term performance. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Baron Funds discussed stocks like argenx SE (NASDAQ:ARGX) in the Q3 2022 investor letter. Headquartered in Breda, the Netherlands, argenx SE (NASDAQ:ARGX) is a biotechnology company. On October 31, 2022, argenx SE (NASDAQ:ARGX) stock closed at $387.93 per share. One-month return of argenx SE (NASDAQ:ARGX) was 5.00% and its shares gained 20.83% of their value over the last 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $21.462 billion.

Here is what Baron Funds specifically said about argenx SE (NASDAQ:ARGX) in its Q3 2022 investor letter:

“argenx SE (NASDAQ:ARGX) is a biotechnology company focused on autoimmune disorders. Shares gave back some gains in the quarter following strong stock performance relative to the broad market and biotechnology indexes. Sales of newly launched drug Vyvgart have tripled consensus expectations, and global approvals are coming earlier than guided. With numerous anticipated catalysts in the months ahead, including readouts in chronic immune demylinating polyneuropathy and myositis and their subcutaneous formulation launch, we expected solid performance through the rest of 2022 and 2023.”

Tonhom1009/Shutterstock.com

argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held argenx SE (NASDAQ:ARGX) at the end of the second quarter which was 31 in the previous quarter.

We discussed argenx SE (NASDAQ:ARGX) in another article and shared the best international stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.